thank you very much for information
Eligibility
Ages Eligible for Study:
18 Years and older
Genders Eligible for Study:
Both
Accepts Healthy Volunteers:
No
Criteria
Inclusion Criteria:
•Documented HIV infection prior to study entry
•Must be willing to comply with study-mandated evaluations; including not changing their antiretroviral regimen (unless medically indicated) during the study period.
Cohort 1, 2 and 3 (Enrollment Completed)
Cohort 5:
•Must have received HAART therapy, and had undetectable viral loads for at least 1 year.
•HIV-1 RNA 350 cells/mm3
•Heterozygous for the CCR5 delta-32 mutation
•On stable antiretroviral medication (no changes to treatment within 4 weeks of screening and willing to discontinue current antiretroviral therapy during the structured therapy interruption
Cohort 4
•On stable antiretroviral medication (no changes to treatment within 4 weeks of screening and willing to continue on current antiretroviral therapy through week 8 after infusion
•CD4+ T cell count >350 cells/mm3.
•HIV-1 >1,000 copies/mL at screen and not responding to current antiviral therapy (i.e. HIV-RNA plasma levels > 1000 copies/ml after at least 12 weeks of stable, unchanged ARV therapy).
Estimated Study Completion Date: December 2013